Lantheus Holdings' LNTH-2513 Wins SNMMI’s 2026 'Image of the Year' for DVT Diagnostics.

- Lantheus Holdings' LNTH-2513 (18F-GP1) PET/CT received SNMMI’s 2026 'Image of the Year' for diagnosing DVT and pulmonary embolism.
- The trial for LNTH-2513 demonstrated exceptional accuracy and safety, effectively visualizing DVT and identifying active thrombi.
- Lantheus aims to leverage this recognition for increased R&D, market adoption, and improved patient care through advanced diagnostics.
Lantheus Holdings (LNTH) has recently received notable acclaim in the realm of diagnostic imaging with its investigational product, LNTH-2513 (18F-GP1) PET/CT, which has been awarded SNMMI’s 2026 'Image of the Year'.
Remarkable Trial Results Highlight Diagnostic Accuracy
This recognition comes from groundbreaking results of an investigator-led trial demonstrating the product's exceptional accuracy in diagnosing acute lower-extremity deep vein thrombosis (DVT), along with its ability to detect associated pulmonary embolism. The trial's findings illustrate that LNTH-2513 not only effectively visualizes DVT but also uncovers active thrombi throughout the body, highlighting its potential to identify various medical conditions linked to unexpected clots. Furthermore, the absence of drug-related adverse events reported in the trial emphasizes the safety and efficacy of LNTH-2513 as a diagnostic tool.
Strategic Positioning in the Diagnostics Market
This accolade not only underscores Lantheus Holdings' dedication to innovation within the healthcare landscape but also positions the company advantageously in the diagnostics market. The significant results achieved with LNTH-2513 present a compelling case for both increased research and development efforts and broadened market adoption. By showcasing its effectiveness and safety, Lantheus can leverage this honor to attract further investment and collaboration opportunities aimed at enhancing diagnostics capabilities.
Looking Ahead: Commitment to Advanced Imaging Technologies
The recognition from SNMMI is expected to catalyze Lantheus’ ongoing commitment to improving patient care through advanced medical imaging technologies. It reinforces the company’s mission to provide cutting-edge tools that facilitate accurate diagnoses, thereby enabling healthcare providers to make informed clinical decisions. Looking ahead, Lantheus Holdings is poised to build upon this success, continuing its trajectory of innovation and excellence in the diagnostic imaging sector, catering to the evolving needs of healthcare providers and patients alike.
Related Cashu News

Pulse Biosciences to Redeem Remaining Common Stock Warrants Following Share Price Conditions
Pulse Biosciences (Ticker: PLSE) implements a significant strategic decision as it moves to redeem the remaining common stock warrants from its rights offering dated July 3, 2024. This action comes in…

LivaNova PLC Board Changes Signal Strategic Shift and Enhanced Governance Amid Regulatory Challenges
LivaNova PLC (Ticker: LIVN) has made significant changes to its Board of Directors, which point to a strategic shift in its operational and risk management approaches. The company recently appointed J…

Penumbra's THUNDERBOLT Technology Receives FDA Clearance for Acute Ischemic Stroke Management
Penumbra, Inc. has achieved a significant milestone with the clearance of its innovative THUNDERBOLT™ technology by the U.S. Food and Drug Administration (FDA). This advancement plays a critical role…

Zimmer Biomet Drives Innovation in Orthopedics with Cementless Implants and Robotic Surgery Solutions
Zimmer Biomet Holdings is making strides in the orthopedic medical device industry, particularly with its innovative cementless implants and ROSA robotic-assisted surgery platform. These technological…